title: [Treatment of mineral bone disorder with pharmaceuticals which influence the calcium phosphor turnover].
abstract: This review discusses the mineral bone disorders in patients with chronic kidney disease. We focus on the management of these conditions by administration of calcium, vitamin D (ergocalciferol and cholecalciferol), vitamin D receptor activators (calcitriol, alphacalcidiol), phosphate binders and calcimimetics (cinacalcet).
authors.affiliation: Endokrinologisk Afdeling, Medicinerhuset, Aalborg Sygehus Syd, Mølleparkvej 4, Aalborg. p-vest@post4.tele.dk
authors.forename: Peter
authors.initials: P
authors.lastname: Vestergaard
authors.forename: Pia A
authors.initials: PA
authors.lastname: Eiken
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D001851:Bone Diseases, Metabolic / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D002118:Calcium / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D003937:Diagnosis, Differential; D005919:Glomerular Filtration Rate; D006801:Humans; D006961:Hyperparathyroidism / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism; D010281:Parathyroid Hormone / Q000378:metabolism; D010710:Phosphates / Q000008:administration & dosage / Q000378:metabolism*; D051436:Renal Insufficiency, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D014807:Vitamin D / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*
chemical_list: D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D010710:Phosphates; D014807:Vitamin D; D002118:Calcium